AIM AIM ImmunoTech Inc.
Debt Financing ·
AIM ImmunoTech converted approximately $1,224,341 of a February 16, 2024 promissory note held by Streeterville Capital, LLC into 5,065,840 shares, and the note was satisfied in full as of September 3, 2026.
The NYSE American said on June 12, 2026 that AIM had resolved its stockholders' equity deficiencies after a series of share sales and warrant exercises in May and June.
The company said on June 4, 2026 that its virtual investor video discusses Ampligen's Ebola research, and that an updated Ebola-focused presentation is available on its website.
The note is now due June 30, 2027. The balance is about $1.68 million after the amendment and the extension fee.
The company said the on-demand segment features an Erasmus MC surgeon who discusses named patient program results and interim data from the ongoing Phase 2 trial.
Existing holders agreed to exercise warrants at $0.48 a share in exchange for new Class H warrants, with gross proceeds of approximately $4.20 million if all existing warrants are exercised.
The amendment names Maxim Group LLC as exclusive sales agent and removes the limit on the amount of shares that can be sold under the agreement.
AIM ImmunoTech sold units at $4.00 with two warrants each, a month after a 1-for-100 reverse split, and its prospectus says there is likely substantial doubt about its ability to continue as a going concern. It must lift stockholders' equity to at least $6 million by June 11, 2026.
AIM ImmunoTech had a stockholders' deficit of negative $3.9 million at March 31, 2025, and its 2024 net loss was approximately $17,320,000. Its tax-loss sales are capped, and the exchange deadline to fix the deficit is June 11, 2026.
AIM ImmunoTech regained NYSE American compliance on its low selling price test after a 1-for-100 reverse split effective June 12, 2025, with trading under AIM due to resume June 17. Its 2024 annual report carries a going-concern warning and a working capital deficit, and a separate stockholders' equity notice from December 2024 is not covered by this filing.
NYSE American suspended trading in AIM ImmunoTech (NYSE American: AIM) and began delisting proceedings, citing the low selling price of the stock. The company plans to appeal and expects Pink Open Market trading on April 7, 2025.
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida. It develops therapeutics for multiple types of cancers, viral diseases and immune-deficiency disorders. Its flagship product is Ampligen (rintatolimod), a double-stranded RNA molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the FDA or marketed in the United States, but it is approved for commercial sale in the Argentine Republic for severe Chronic Fatigue Syndrome. AIM has chosen to focus on late-stage pancreatic cancer. Its investigator-initiated Phase 2 DURIPANC study combines Ampligen with AstraZeneca's Imfinzi (durvalumab) in metastatic pancreatic cancer patients, with eighteen patients enrolled. In March 2026, AIM announced an agreement with the PPD clinical research business of Thermo Fisher Scientific to design an anticipated Phase 3 trial. Other programs cover antiviral uses, ME/CFS and Ampligen as a vaccine adjuvant with AstraZeneca's FluMist. The company also lists Alferon N Injection (Interferon alfa) among its products.
| Product or program | What it is | Stage |
|---|---|---|
| Ampligen (rintatolimod) | Double-stranded RNA molecule for cancers, viral diseases and immune disorders | Approved for severe Chronic Fatigue Syndrome in Argentina; not approved by the FDA |
| DURIPANC study (Ampligen with Imfinzi) | Combination for metastatic pancreatic cancer after FOLFIRINOX | Phase 2 |
| Alferon N Injection | Interferon alfa product |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $88,000 | $170,000 |
| Research and development | $3.9 million | $6.2 million |
| Net income (loss) | -$14.0 million | -$17.3 million |
| Cash from operations | -$11.0 million | -$14.9 million |
| Cash and equivalents | $3.0 million | $1.7 million |
| Short-term investments | $62,000 | $2.3 million |
Our latest story on this, dated Jul 30, 2025: "AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 7, 2025: "AIM ImmunoTech gets NYSE American delisting notice over low stock price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 30, 2025: "AIM ImmunoTech prices $8.0 million unit offering as it works to fix equity shortfall". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 10, 2026: "AIM ImmunoTech amends at-the-market sales agreement with Maxim Group". The story links the filing or release it is based on. Read the story.
AIM ImmunoTech Inc. trades under the ticker AIM on AMEX.
AIM ImmunoTech Inc. is listed on AMEX. Our directory also records these other listings: LSE:0A4Y.
The SEC Central Index Key (CIK) for AIM ImmunoTech Inc. is 946644. Its filings are on SEC EDGAR.
30,442,139 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-07.
Our directory records AIM ImmunoTech Inc. under United States.
Our directory classifies AIM ImmunoTech Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for AIM ImmunoTech Inc. is US00901B3033.
aibio.space lists AIM ImmunoTech Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida. It develops therapeutics for multiple types of cancers, viral diseases and immune-deficiency disorders.
Ampligen (rintatolimod): Double-stranded RNA molecule for cancers, viral diseases and immune disorders Stage: Approved for severe Chronic Fatigue Syndrome in Argentina; not approved by the FDA.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio